melatonin has been researched along with Respiratory Distress Syndrome in 7 studies
Respiratory Distress Syndrome: A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acute lung injury (ALI)/ acute respiratory distress syndrome (ARDS) is featured by intensive inflammatory responses and oxidative stress, which lead to cytokine storms and pyroptosis." | 5.72 | Melatonin attenuates LPS-induced pyroptosis in acute lung injury by inhibiting NLRP3-GSDMD pathway via activating Nrf2/HO-1 signaling axis. ( Ding, ZX; Fei, GH; Kang, JY; Shen, JL; Sun, Y; Wang, YG; Wei, YY; Wu, HM; Xu, MM; Zhang, DW, 2022) |
| " Included in this group of conditions is asphyxia, respiratory distress syndrome and sepsis and the review also summarizes the literature related to clinical trials of antioxidant therapies and of melatonin, a highly effective antioxidant and free radical scavenger." | 4.85 | Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin. ( Barberi, I; Gitto, E; Gitto, P; Pellegrino, S; Reiter, RJ, 2009) |
| "Acute lung injury (ALI)/ acute respiratory distress syndrome (ARDS) is featured by intensive inflammatory responses and oxidative stress, which lead to cytokine storms and pyroptosis." | 1.72 | Melatonin attenuates LPS-induced pyroptosis in acute lung injury by inhibiting NLRP3-GSDMD pathway via activating Nrf2/HO-1 signaling axis. ( Ding, ZX; Fei, GH; Kang, JY; Shen, JL; Sun, Y; Wang, YG; Wei, YY; Wu, HM; Xu, MM; Zhang, DW, 2022) |
| "Melatonin was administered at a dose of 100 mg/kg using an intraperitoneal injection." | 1.34 | The histopathological evaluation of the effectiveness of melatonin as a protectant against acute lung injury induced by radiation therapy in a rat model. ( Erkal, HS; Gülbaş, H; Gürses, I; Serin, M; Yücel, N, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, JY | 1 |
| Xu, MM | 1 |
| Sun, Y | 1 |
| Ding, ZX | 1 |
| Wei, YY | 1 |
| Zhang, DW | 1 |
| Wang, YG | 1 |
| Shen, JL | 1 |
| Wu, HM | 1 |
| Fei, GH | 1 |
| Zhang, R | 1 |
| Wang, X | 1 |
| Ni, L | 1 |
| Di, X | 1 |
| Ma, B | 1 |
| Niu, S | 1 |
| Liu, C | 1 |
| Reiter, RJ | 2 |
| Sun, CK | 1 |
| Lee, FY | 1 |
| Kao, YH | 1 |
| Chiang, HJ | 1 |
| Sung, PH | 1 |
| Tsai, TH | 1 |
| Lin, YC | 1 |
| Leu, S | 1 |
| Wu, YC | 1 |
| Lu, HI | 1 |
| Chen, YL | 1 |
| Chung, SY | 1 |
| Su, HL | 1 |
| Yip, HK | 1 |
| Zhang, L | 1 |
| He, D | 1 |
| Shao, Y | 1 |
| Xu, D | 1 |
| Shen, J | 1 |
| Gitto, E | 1 |
| Pellegrino, S | 1 |
| Gitto, P | 1 |
| Barberi, I | 1 |
| Mohan, S | 1 |
| Brunner, HE | 1 |
| Serin, M | 1 |
| Gülbaş, H | 1 |
| Gürses, I | 1 |
| Erkal, HS | 1 |
| Yücel, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.[NCT04353128] | Phase 2/Phase 3 | 450 participants (Actual) | Interventional | 2020-04-20 | Completed | ||
| A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection[NCT04784754] | Phase 2 | 0 participants (Actual) | Interventional | 2021-04-01 | Withdrawn (stopped due to lack of subject enrollment) | ||
| A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection[NCT04474483] | Phase 2 | 8 participants (Actual) | Interventional | 2020-11-06 | Terminated (stopped due to difficult recruitment and complete first visit in person during thne hight of tne pandemic and later not enough subjects) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for melatonin and Respiratory Distress Syndrome
| Article | Year |
|---|---|
COVID-19: Melatonin as a potential adjuvant treatment.
Topics: Acute Lung Injury; Adjuvants, Immunologic; Anti-Inflammatory Agents; Antioxidants; Betacoronavirus; | 2020 |
COVID-19: Melatonin as a potential adjuvant treatment.
Topics: Acute Lung Injury; Adjuvants, Immunologic; Anti-Inflammatory Agents; Antioxidants; Betacoronavirus; | 2020 |
COVID-19: Melatonin as a potential adjuvant treatment.
Topics: Acute Lung Injury; Adjuvants, Immunologic; Anti-Inflammatory Agents; Antioxidants; Betacoronavirus; | 2020 |
COVID-19: Melatonin as a potential adjuvant treatment.
Topics: Acute Lung Injury; Adjuvants, Immunologic; Anti-Inflammatory Agents; Antioxidants; Betacoronavirus; | 2020 |
COVID-19: Melatonin as a potential adjuvant treatment.
Topics: Acute Lung Injury; Adjuvants, Immunologic; Anti-Inflammatory Agents; Antioxidants; Betacoronavirus; | 2020 |
COVID-19: Melatonin as a potential adjuvant treatment.
Topics: Acute Lung Injury; Adjuvants, Immunologic; Anti-Inflammatory Agents; Antioxidants; Betacoronavirus; | 2020 |
COVID-19: Melatonin as a potential adjuvant treatment.
Topics: Acute Lung Injury; Adjuvants, Immunologic; Anti-Inflammatory Agents; Antioxidants; Betacoronavirus; | 2020 |
COVID-19: Melatonin as a potential adjuvant treatment.
Topics: Acute Lung Injury; Adjuvants, Immunologic; Anti-Inflammatory Agents; Antioxidants; Betacoronavirus; | 2020 |
COVID-19: Melatonin as a potential adjuvant treatment.
Topics: Acute Lung Injury; Adjuvants, Immunologic; Anti-Inflammatory Agents; Antioxidants; Betacoronavirus; | 2020 |
Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin.
Topics: Animals; Asphyxia Neonatorum; Clinical Trials as Topic; Female; Free Radical Scavengers; Humans; Inf | 2009 |
5 other studies available for melatonin and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Melatonin attenuates LPS-induced pyroptosis in acute lung injury by inhibiting NLRP3-GSDMD pathway via activating Nrf2/HO-1 signaling axis.
Topics: Acute Lung Injury; Animals; Heme Oxygenase-1; Lipopolysaccharides; Melatonin; Membrane Proteins; Mic | 2022 |
Systemic combined melatonin-mitochondria treatment improves acute respiratory distress syndrome in the rat.
Topics: Animals; Blotting, Western; Male; Melatonin; Microscopy, Electron, Transmission; Mitochondria; Oxyge | 2015 |
[Effect of melatonin on p38MAPKsignaling pathway in rats with phosgene-induced lung injury].
Topics: Animals; Bronchoalveolar Lavage Fluid; Chemical Warfare Agents; Imidazoles; Lung; Lung Injury; Male; | 2014 |
Melatonin in critically ill patients.
Topics: Adult; Critical Care; Humans; Male; Melatonin; Respiratory Distress Syndrome; Sepsis; Sleep Wake Dis | 2005 |
The histopathological evaluation of the effectiveness of melatonin as a protectant against acute lung injury induced by radiation therapy in a rat model.
Topics: Animals; Gamma Rays; Lung; Lung Injury; Macrophages, Alveolar; Male; Melatonin; Radiation Injuries, | 2007 |